Author: Natalia Hotsaliuk

Breakthrough test provides clarity for prostate cancer diagnosis

Natalia Hotsaliuk2024-09-09T21:55:20+00:00

With support from the Canadian Cancer Society, Dr John Lewis took his research to new heights with an innovative test for prostate cancer screening.

“This test can tell you if you have a low or high risk of aggressive prostate cancer,” Dr Lewis says. “It’s an addition to the PSA test and designed to give men and their doctors more clarity so they can make informed decisions about whether to proceed with a biopsy.”

Click below to read the full article.

Full Article

Breakthrough test provides clarity for prostate cancer diagnosisNatalia Hotsaliuk2024-09-09T21:55:20+00:00

Nanostics Gets Featured on Global News

Natalia Hotsaliuk2024-07-31T16:08:31+00:00

Prostate cancer is one of the most common cancers among men in Canada and early detection can save lives. See Nicole Stillger from Global News explain how ClarityDX Prostate works, and how support from Alberta Innovates helps advance our research.

Video

Nanostics Gets Featured on Global NewsNatalia Hotsaliuk2024-07-31T16:08:31+00:00

Research supporting ClarityDX Prostate published in Nature Digital Medicine

Natalia Hotsaliuk2024-07-03T19:51:25+00:00

Published 26 June 2024

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

M. Eric Hyndman, Robert J. Paproski, Adam Kinnaird, Adrian Fairey, Leonard Marks, Christian P. Pavlovich, Sean A. Fletcher, Roman Zachoval, Vanda Adamcova, Jiri Stejskal, Armen Aprikian, Christopher J. D. Wallis, Desmond Pink, Catalina Vasquez, Perrin H. Beatty & John D. Lewis

Abstract

The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa. Integrating the ClarityDX platform with blood-based biomarkers for clinically significant PCa and clinical biomarker data from a 3448-patient cohort, we developed a test to stratify patients’ risk of csPCa; called ClarityDX Prostate. When predicting high risk cancer in the validation cohort, ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value, at a ≥ 25% threshold. Using ClarityDX Prostate at this threshold could avoid up to 35% of unnecessary prostate biopsies. ClarityDX Prostate showed higher accuracy for predicting the risk of csPCa than PSA alone and the tested model-based risk calculators. Using this test as a reflex test in men with elevated PSA levels may help patients and their healthcare providers decide if a prostate biopsy is necessary.

Full Article

Research supporting ClarityDX Prostate published in Nature Digital MedicineNatalia Hotsaliuk2024-07-03T19:51:25+00:00

Best Startup Workplace of the Year

Natalia Hotsaliuk2024-05-07T22:46:59+00:00

Nanostics is thrilled to announce that we’ve been awarded Best Startup Workplace of the Year in the 2024 YEG Startup Community Awards! We extend heartfelt congratulations to all the nominees. We also express our gratitude to the YEG Startup Community volunteers for their organization of this exceptional event.

This achievement speaks volumes about the incredible culture created by our team of dedicated employees. Their hard work, dedication, and commitment to excellence have truly set us apart. We are immensely grateful for their contributions in making Nanostics a truly exceptional workplace. Thank you to each and every member of our team for your unwavering efforts. Together, we continue to drive innovation forward!

Best Startup Workplace of the YearNatalia Hotsaliuk2024-05-07T22:46:59+00:00

About Natalia Hotsaliuk

Follow Us

Contact Us